Literature DB >> 10959094

Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples.

D Angeloni1, A Danilkovitch-Miagkova, S V Ivanov, R Breathnach, B E Johnson, E J Leonard, M I Lerman.   

Abstract

The human RON gene (MST1R) maps to 3p21.3, a region frequently altered in lung cancer and other malignancies. It encodes a receptor tyrosine kinase (RTK) closely related to MET, whose mutations are associated with neoplasia. We investigated whether RON might be involved in the development or progression of lung cancer. We first determined the exon-intron structure of the gene by direct sequencing of RON cosmid DNA and PCR products containing intronic sequences, and then developed primers suitable for mutation analysis by the single-strand conformation polymorphism (SSCP) method. Twenty coding exons were characterized, all but the first one small (average size: 170 bp), a feature shared with other RTK genes. We performed SSCP analysis of RON in small and non-small cell lung cancer samples, upon detection of its expression in a sample of lung cancer cell lines. A mutation (T915C: L296P) was found in an adenocarcinoma specimen. Several single nucleotide polymorphisms were also found. The panel of intron-anchored primers developed in this work will be useful for mutation analysis of the RON gene in different types of human tumors. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10959094

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  19 in total

Review 1.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

2.  Prognostic significance of MST1R dysregulation in renal cell tumors.

Authors:  Ana S Pires-Luís; Márcia Vieira-Coimbra; Maria João Ferreira; João Ramalho-Carvalho; Pedro Costa-Pinheiro; Luís Antunes; Paula C Dias; Francisco Lobo; Jorge Oliveira; Inês Graça; Rui Henrique; Carmen Jerónimo
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

Review 3.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

4.  RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.

Authors:  Daniel V T Catenacci; Gustavo Cervantes; Soheil Yala; Erik A Nelson; Essam El-Hashani; Rajani Kanteti; Mohamed El Dinali; Rifat Hasina; Johannes Brägelmann; Tanguy Seiwert; Michele Sanicola; Les Henderson; Tatyana A Grushko; Olufunmilayo Olopade; Theodore Karrison; Yung-Jue Bang; Woo Ho Kim; Maria Tretiakova; Everett Vokes; David A Frank; Hedy L Kindler; Heather Huet; Ravi Salgia
Journal:  Cancer Biol Ther       Date:  2011-07-01       Impact factor: 4.742

5.  Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein.

Authors:  Kinlin L Chao; Natalia V Gorlatova; Edward Eisenstein; Osnat Herzberg
Journal:  J Biol Chem       Date:  2014-09-05       Impact factor: 5.157

6.  Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers.

Authors:  Jocelyn Logan-Collins; Ryan M Thomas; Peter Yu; Dawn Jaquish; Evangeline Mose; Randall French; William Stuart; Rebecca McClaine; Bruce Aronow; Robert M Hoffman; Susan E Waltz; Andrew M Lowy
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701

7.  Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.

Authors:  Qi Ma; Kun Zhang; Sunny Guin; Yong-Qing Zhou; Ming-Hai Wang
Journal:  Mol Cancer       Date:  2010-11-29       Impact factor: 27.401

8.  The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Qi Ma; Sunny Guin; Snehal S Padhye; Rui-Wen Zhang; Ming-Hai Wang
Journal:  Mol Cancer       Date:  2011-07-12       Impact factor: 27.401

9.  SRSF2 promotes splicing and transcription of exon 11 included isoform in Ron proto-oncogene.

Authors:  Heegyum Moon; Sunghee Cho; Tiing Jen Loh; Hyun Kyung Oh; Ha Na Jang; Jianhua Zhou; Young-Soo Kwon; D Joshua Liao; Youngsoo Jun; Soohyun Eom; Claudia Ghigna; Giuseppe Biamonti; Michael R Green; Xuexiu Zheng; Haihong Shen
Journal:  Biochim Biophys Acta       Date:  2014-09-08

10.  Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.

Authors:  Kinlin L Chao; I-Wei Tsai; Chen Chen; Osnat Herzberg
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.